Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Legend Biotech (LEGN) over the last 2 years, with Sep 2025 value amounting to $369.3 million.

  • Legend Biotech's Shares Outstanding (Diluted Average) was N/A to $369.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $369.3 million, marking a year-over-year change of. This contributed to the annual value of $318.1 million for FY2022, which is 12.91% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Shares Outstanding (Diluted Average) is $369.3 million, which was up 16.09% from $318.1 million recorded in Q4 2022.
  • Legend Biotech's 5-year Shares Outstanding (Diluted Average) high stood at $369.3 million for Q3 2025, and its period low was $266,294 during Q1 2021.
  • Moreover, its 1-year median value for Shares Outstanding (Diluted Average) was $369.3 million (2025), whereas its average is $369.3 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first tumbled by 99.87% in 2021, then soared by 115,824.18% in 2022.
  • Over the past 3 years, Legend Biotech's Shares Outstanding (Diluted Average) (Quarterly) stood at $281.7 million in 2021, then rose by 12.91% to $318.1 million in 2022, then reached $369.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $369.3 million in Q3 2025, compared to $318.1 million in Q4 2022 and $308.7 million in Q1 2022.